NEW YORK (GenomeWeb) – Maverix Biomics and Elsevier have signed an agreement that lets the companies integrate the Maverix Analytic platform with Elsevier's Pathway Studio software to improve the analysis and interpretation of next-generation sequencing data.
The companies made the announcement at the 23rd International Molecular Medicine Tri-Conference being held this week in San Francisco, Calif.
Customers of the integrated offering will have access to published information from Elsevier journals as well as tools for aligning raw sequences, for variant and expression analysis, and for analyzing and visualizing disease mechanisms. Access to both solutions will enable customers to save time, reduce workloads, and improve the accuracy of their results, Jaqui Hodgkinson, vice president, product development of Elsevier Life Sciences Solutions, said in statement.
Financial and other terms of the agreement were not disclosed.